Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note

13.06.24 00:00 Uhr

Werte in diesem Artikel
Aktien

71,00 EUR 1,00 EUR 1,43%

604,00 JPY -8,00 JPY -1,31%

Indizes

5.452,1 PKT 24,9 PKT 0,46%

In the latest market close, Boston Scientific (BSX) reached $77.41, with a +0.34% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Shares of the medical device manufacturer have appreciated by 4.98% over the course of the past month, outperforming the Medical sector's gain of 2.46% and the S&P 500's gain of 3.11%.Market participants will be closely following the financial results of Boston Scientific in its upcoming release. On that day, Boston Scientific is projected to report earnings of $0.58 per share, which would represent year-over-year growth of 9.43%. Alongside, our most recent consensus estimate is anticipating revenue of $4.02 billion, indicating a 11.68% upward movement from the same quarter last year.For the full year, the Zacks Consensus Estimates are projecting earnings of $2.32 per share and revenue of $15.99 billion, which would represent changes of +13.17% and +12.3%, respectively, from the prior year.Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 33.24. This indicates a premium in contrast to its industry's Forward P/E of 23.62.It is also worth noting that BSX currently has a PEG ratio of 2.65. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.14 at yesterday's closing price.The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 138, placing it within the bottom 46% of over 250 industries.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.Top 5 Dividend Stocks for Your RetirementZacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.See our Top 5 now – the report is FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Boston Scientific

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Boston Scientific Corp.

Analysen zu Boston Scientific Corp.

DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
28.04.2016Boston Scientific NeutralWedbush Morgan Securities Inc.
04.05.2015Boston Scientific HoldDeutsche Bank AG
05.02.2015Boston Scientific HoldDeutsche Bank AG
30.09.2014Boston Scientific HoldNeedham & Company, LLC
07.01.2013Boston Scientific haltenDeutsche Bank Securities
DatumRatingAnalyst
13.04.2010Boston Scientific "sell"Goldman Sachs Group Inc.
17.03.2010Boston Scientific DowngradeGoldman Sachs Group Inc.
10.10.2008Boston Scientific below averageCaris & Company, Inc.
02.10.2008Boston Scientific DowngradeMerrill Lynch & Co., Inc.
13.12.2007Boston Scientific underperformFriedman, Billings Ramsey & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Boston Scientific Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"